-
1Academic Journal
Authors: V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan, P. V. Krivorotko, V. G. Ivanov, E. K. Zhiltsova, R. M. Paltuev, L. M. Bershtein, T. Yu. Semiglazova, S. S. Yerechshenko, V. V. Klimenko, V. S. Apollonova, A. V. Komyahov, A. A. Bessonov, В. Ф. Семиглазов, В. В. Семиглазов, Г. А. Дашян, П. В. Криворотько, В. Г. Иванов, Е. К. Жильцова, Р. М. Палтуев, Л. М. Берштейн, Т. Ю. Семиглазова, С. С. Ерещенко, В. В. Клименко, В. С. Аполлонова, А. В. Комяхов, А. А. Бессонов
Source: Siberian journal of oncology; Том 17, № 3 (2018); 11-19 ; Сибирский онкологический журнал; Том 17, № 3 (2018); 11-19 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2018-17-3
Subject Terms: гормонзависимые опухоли, neoadjuvant endocrine therapy, ER+ breast cancer, hormone-dependent tumors, неоадъювантная эндокринотерапия, эстроген-рецептор-положительные опухоли
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/758/532; Семиглазов В.Ф., Криворотько П.В., Семиглазова Т.Ю., Николаев К.С., Комяхов А.В., Дашян Г.А., Семиглазов В.В., Палутев Р.М. Рекомендации по лечению рака молочной железы. М.: Мегаполис, 2017. 168; Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., Senn H.J.; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24 (9): 2206–23. doi:10.1093/annonc/mdt303.; Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., Mauriac L., Ellis M., Lassus M., Chaudri-Ross H.A., Dugan M., Borgs M.; Letrozole Neo- Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001 Nov; 12 (11): 1527–32.; Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Jänicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe- Fehling E., Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001 Sep 15; 19 (18): 3808–16. doi:10.1200/JCO.2001.19.18.3808.; Smith I.E., Dowsett M. Comparison of anastozole vs. tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptorpositive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer. Res. 2003; 82: S6.; Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Ziltsova E.K., Ivanov V.G., Bozhok A.A., Berstein L.M. Phase II randomized trial of primary endocrine therapy chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer. 2007, 110 (2): 244–254.; Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Petrenko O.L., Komyahov A.V., Paltuev R.M., Matzko D. P198 Prognostic values of breast cancer subtypes : from phase 2 randomized trial of neoadjuvant therapy. The Breast, 2015; 24: S92.; Cardoso F., Costa A., Norton L., Senkus E., Aapro M., Andre F., Cardoso M.J. ESO-ESMO 2nd international consensus guidelines for advanced breast Cancer (ABC2). Simultaneous And Annals of Oncology. 2014: 25: 1871–1888.; Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., Ettl J., Patel R., Pinter T., Schmidt M., Shparyk Y., Thummala A.R., Voytko N.L., Fowst C., Huang X., Kim S.T., Randolph S., Slamon D.J. The cyclin – dependent kinase 4/6 inhibitor palbociclib on combination with letrozole versus letrozole alone as first-line treatment of estrogen receptorpositive, HER2- negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. Lancet Oncol. 2015 Jan; 16 (1): 25–35. doi:10.1016/S1470-2045(14)71159-3.; Turner N.C., Huang Bartlett C., Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Oct 22; 373 (17): 1672–3. doi:10.1056/NEJMc1510345.; Finn R.S., Martin M., Rugo H.S., Jones S.E., Im S.A., Gelmon K.A., Gauthier E.R. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ERb/HER2e advanced breast cancer (ABC). J Clin Oncol 2016; 34. Abstr 507.; Weigel R.J., de Coninck E.C. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res. 1993 Aug 1; 53 (15): 3472–4.; Fribbens C., O’Leary B., Kilburn L., Hrebien S., Garcia-Murillas I., Beaney M., Cristofanilli M., Andre F., Loi S., Loibl S., Jiang J., Bartlett C.H., Koehler M., Dowsett M., Bliss J.M., Johnston S.R., Turner N.C. Plasma ESR1 mutations and the treatment of estrogen receptor- positive advanced breast cancer. J Clin Oncol. 2016 Sep 1; 34 (25): 2961–8. doi:10.1200/JCO.2016.67.3061; Harbeck N., Iyer S., Turner N., Cristofanilli M., Ro J., André F., Loi S., Verma S., Iwata H., Bhattacharyya H., Puyana Theall K., Bartlett C.H., Loibl S. Quality of life with palbociclib plus full-vestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016 Jun; 27 (6): 1047–54. doi:10.1093/annonc/mdw139.; Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., Abadie- Lacourtoisie S., Eymard J.C., Debled M., Spaëth D., Legouffe E., Allouache D., El Kouri C., Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012 Aug 1; 30 (22): 2718–24. doi:10.1200/JCO.2011.39.0708.; https://www.siboncoj.ru/jour/article/view/758
-
2Academic Journal
Authors: В. Ф. Семиглазов, В. В. Семиглазов, А. Г. Манихас, Г. А. Дашян, В. Г. Иванов, Т. Ю. Семиглазова, Р. М. Палтуев
Source: Malignant tumours; Том 2, № 2 (2012); 6-11 ; Злокачественные опухоли; Том 2, № 2 (2012); 6-11 ; 2587-6813 ; 2224-5057
Subject Terms: постменопаузальный период, неоадъювантная эндокринотерапия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/21/25; Семиглазов В.Ф., Манихас А.Г., Семиглазова Т.Ю., Бессонов А.А., Семиглазов В.В. Неоадъювантная системная терапия рака молочной железы. (Руководство). Аграф., 2012.-112 с.; Семиглазов В.Ф., Семиглазов B.B., Дашян Г.А. Эндокринотерапия раннего рака молочной железы. Руководство. М., «МЕДпресс-информ»,- 2011 -96 с.; Aebi S, Sun Z, Braun D et al.’Differential efficacy of three cycles of CMF followed by tamoxifen in patients with HR-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Ann Oncol 2011; - Vol. - 22, pp. 179-189.; Albain KS, Barlow WE, Ravdin PM et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node- positive breast cancer: a phase 3, open-label, randomized controlled trial. Lancet 2009; - Vol. - 374: pp 2055-2063.; Baselga J., Semiglazov V., van Dam P. et.al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor - positive breast cancer // J.Clin Oncol - 2009. -Vol.-27(6).-p. 2630-2637Ю; Colleoni M, Adjuvant therapies for special types of breast cancer (abstr. S240)// The Breast. – 2011. – Vol. 20 (suppl.1). – P.15; Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2 – positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2 – negative cohort // Lancet. – 2010. – Vol.375.- P.377-384.; Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal В breast cancer. J Natl Cancer Inst 2009; Vol.-101: pp. 736-750.; Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the-Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; - Vol. - 20: pp. 1319-1329.; Johnston J. How to treat ER – positive HER2 – positive breast cancer. J Clin Oncol., 2009 – vol.27.- p.5529-5538.; Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; - Vol. - 26: pp. 1275-1281.; Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; - Vol. - 109: pp. 123-139.; Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; - Vol. - 26: pp.2373-2378.; Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; - Vol. - 27: pp.1160- 1167.; Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; - Vol. - 406: pp. 747-752.; Phipps Al, Buist DS, Malone KE et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011; - Vol. - 22: pp.399-405.; Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011 - Vol. -;5: pp. 5-23.; Semiglazov V.F., Semiglazov V.V., Ivanov V. et al. The relative efficacy of neoadjuvant endocrine therapy vs postmenopausal women with ER-positive breast cancer // J. Clin. Oncol. - 2004. - vol. 22. - p. 519.; Semiglazov V.F., Semigiazov V.V., Dashyan G. et al. Randomized trial of primary endocrine therapy chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer // Cancer. - 2007. - vol. 110 - p. 244 -254.; Tang G, Shak S, Paik S et al. Comparison of the prognostic and predictive utilities of the 21- gene recurrence score assay and Adjuvant! for women with nodenegative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011; - Vol. - 320: pp. 1112-1120.; Wo JY, Taghian AG, Nguyen PL et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys 2010; - Vol. - 77: pp. 188-196.; https://www.malignanttumors.org/jour/article/view/21
-
3Academic Journal
Authors: СЕМИГЛАЗОВ В.Ф., СЕМИГЛАЗОВ В.В., МАНИХАС А.Г., ДАШЯН Г.А., ИВАНОВ В.Л., СЕМИГЛАЗОВА Т.Ю., ПАЛТУЕВ Р.М.
File Description: text/html
-
4Academic Journal
Source: Злокачественные опухоли.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, РАК МОЛОЧНОЙ ЖЕЛЕЗЫ,НЕОАДЪЮВАНТНАЯ ЭНДОКРИНОТЕРАПИЯ,ПОСТМЕНОПАУЗАЛЬНЫЙ ПЕРИОД
File Description: text/html
